CDC2 has oncogenic properties and also regulates anticancer drug responses, and is considered an emerging target for cancer therapeutic intervention (Jeong et al., 2022; Wavelet-Vermuse et al., 2022) Additionally, CDC20 was reported to be related to immune infiltration in cancer. This evidence concerns the gene CDK1 and cancer.